Rigel Pharma’s $RIGL fostamatinib has upcoming data this month. Data is from a phase 3 trial of fostamatinib in ITP, or immune thrombocytopenic purpura, an autoimmune disease that leads to the destruction of platelets, eventually leading to internal bleeding, and death. Chronic ITP affects an estimated 60,000 to 125,000 people in the U.S.

*** L2 or above subscription required to read the rest of the article ... Login or Subscribe/Upgrade here